实用老年医学 ›› 2022, Vol. 36 ›› Issue (3): 269-272.doi: 10.3969/j.issn.1003-9198.2022.03.014

• 临床研究 • 上一篇    下一篇

通脉养心丸联合替罗非班治疗老年不稳定型心绞痛的临床研究

史建华, 金雷, 柳纪红, 刘爱军   

  1. 117000 辽宁省本溪市,本溪市中心医院心内科
  • 收稿日期:2021-05-21 出版日期:2022-03-20 发布日期:2022-03-29
  • 通讯作者: 刘爱军,Email:sj2002qq@163.com
  • 基金资助:
    中国医学科学院2019年院内科研项目(2018YFC1312404)

Clinical study on Tongmai Yangxin Pill combined with tirofiban in the treatment of elderly patients with unstable angina pectoris

SHI Jian-hua, JIN Lei, LIU Ji-hong, LIU Ai-jun   

  1. Department of Cardiovascular Disease, Benxi Central Hospital, Benxi 117000, China
  • Received:2021-05-21 Online:2022-03-20 Published:2022-03-29

摘要: 目的 探究通脉养心丸联合替罗非班治疗老年不稳定型心绞痛(UAP)的临床疗效。 方法 选取2016年5月至2019年4月,在本溪市中心医院进行治疗的UAP病人121例,使用随机数表法将其分为2组,对照组病人接受盐酸替罗非班氯化钠注射液治疗,观察组在对照组的基础上服用通脉养心丸,治疗8 d后比较2组病人临床疗效、血清学指标、凝血指标及不良事件发生情况。 结果 观察组病人临床有效率高于对照组(P<0.05)。2组病人治疗前血清半乳糖凝集素-3(Gal-3)、人可溶性细胞黏附分子(sICAM-1)、一氧化氮(NO)、超氧化物歧化酶(SOD)水平以及D-二聚体(D-D)、凝血酶原时间(PT)、凝血酶时间(TT)、活化部分凝血活酶时间(APTT)、维维蛋白原(PIB)比较,差异没有统计学意义;治疗后2组Gal-3、ICAM-1、D-D、PT、TT、ATPP、FIB水平显著降低,NO、SOD水平显著升高(P<0.05),且观察组改善更为明显(P<0.05)。与对照组相比,观察组不良事件发生率及复发率显著降低(P<0.05)。 结论 通脉养心丸联合盐酸替罗非班治疗UAP能有效降低体内炎症水平,改善凝血功能,提高临床疗效,且安全性良好。

关键词: 通脉养心丸, 替罗非班, 不稳定型心绞痛, 疗效, 凝血功能

Abstract: Objective To explore the clinical efficacy of Tongmai Yangxin Pill combined with tirofiban in the treatment of elderly patients with unstable angina pectoris (UAP). Methods From May 2016 to April 2019, a total of 121 patients with UAP treated in Benxi Central Hospital were divided into two groups by using random number table method. The control group was injected with tirofiban hydrochloride and sodium chloride, and the observation group took Tongmai Yangxin Pills on the basis of the control group. After 8 days of treatment, the clinical efficacy, serum indexes, coagulation indexes and the adverse events of the two groups were compared. Results The clinical effective rate in the observation group was higher than that in the control group (P<0.05). There were no significant differences in the serum indicators of galectin-3 (Gal-3), intercellular cell adhesion molecule-1 (ICAM-1), nitric oxide (NO), superoxide dismutase (SOD), D-dimer (D-D), prothrombin time (PT), thrombin time (TT), activated partial thromboplastin time (APTT) and fibrinogen (FIB) before treatment between the two groups. After treatment, the levels of Gal-3, NO, D-D, PT, TT, APTT and FIB decreased significantly, and the levels of ICAM-1 and SOD increased significantly in the two groups(P<0.05), especially in the observation group. Compared with the control group, the incidence rate of adverse events and the recurernce rate was significantly lower in the observation group (P<0.05). Conclusions Tongmai Yangxin Pill combined with tirofiban hydrochloride in the treatment of UAP can effectively reduce the level of inflammation, improve the blood coagulation function, and have good safety and clinical efficacy.

Key words: Tongmai Yangxin Pill, tirofiban, unstable angina pectoris, efficacy, coagulation function

中图分类号: